pharma · Obesity, Overweight · Type 2 Diabetes
Eli Lilly and
Eli Lilly Co.
Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 1
Company details
- Status
- Public
- HQ
- Lilly Corporate Center, Indianapolis, Indiana 46285, US
- Founded
- 1876
- Employees
- 55,860
- Programs
- 107
- Drugs
- 99
- Patents
- 0
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Phase 1 · other · Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis
A Study of LY4257496 in Participants With Cancer (OMNIRAY) for Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Internal code J6C-OX-JKFA
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eli Lilly Co.
- Phase
- Phase 1
- Modality
- other
- Indication
- Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis
- Status
- active
- Trials
- 1